KDKaixin Dou

Kaixin Dou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaixin Dou has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study

    by Xiaohui Sun, Kaixin Dou, Li Xue, Yijie Xie, Yong Yang, Anmu Xie

    The Parkinson's Progression Marker Initiative (PPMI) aims to identify biomarkers for Parkinson's disease (PD) risk, onset, and progression. This study focuses on the G2019S missense mutation in the LRRK2 gene, which is associated with hereditary and sporadic PD. Utilizing data from the PPMI database, we conducted an analysis of baseline clinical characteristics, as well as serum and cerebrospinal fluid levels in two groups: patients with PD with the G2019S mutation (PD + G2019S) and patients with PD without the mutation (PD‐G2019S). Multiple linear regression and longitudinal analysis were performed, controlling for confounding factors. Compared to the PD‐G2019S group, the PD + G2019S group showed more obvious initial motor dysfunction—higher baseline Movement Disorder Society‐Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS‐UPDRS) scores (false discovery rate [FDR]‐adjusted p < 0.001), but progressed more slowly. Mechanism of Coordinated Access and activities of daily living (ADL) scores were lower at baseline (FDR‐adjusted p < 0.001), whereas Scales for Outcomes of Parkinson's Disease (SCOPA)‐Thermoregulatory (FDR‐adjusted p = 0.015) scores were higher, emphasizing the increase of non‐motor symptoms associated with LRRK2‐G2019S mutation. During the follow‐up period, the motor and non‐motor symptoms changed dynamically with time, and there were longitudinal differences in the scores of MDS‐UPDRS (FDR‐adjusted PI = 0.013, PII = 0.008, PIV < 0.001), Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease (FDR‐adjusted p = 0.027), SCOPA‐Thermoregulatory (FDR‐adjusted p = 0.021), and ADL (FDR‐adjusted p = 0.027) scale scores. PD associated with the LRRK2 G2019S mutation demonstrated more severe symptoms at baseline but slower progression. Motor complications and thermoregulatory disorders were more pronounced.


  • Open Access

    Repetitive transcranial magnetic stimulation alleviates glial activation through suppressing HMGB1/TLR4 pathway in a rat model of Parkinson’s disease

    by Chao Han, Xue Zhang, Kaixin Dou, Weichao Yao, Minyi Yao, Qi Wan, Anmu Xie

    Background: Repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to be effective in Parkinson’s disease (PD), but whether rTMS treatment has a relieving effect on neuroinflammation remains to be investigated. In this article, we explored the effects of rTMS on forelimb use asymmetry and neuroinflammation-related mechanisms in a 6-hydroxydopamine (6-OHDA)-induced PD rat model. Methods and results: Rats in the 6-OHDA+rTMS group received 10 Hz rTMS daily for 4 weeks. Behavioral tests (the cylinder test) were performed at the 3rd and 7th weeks after the operation. Astrocyte and microglia activation and protein levels of tyrosine hydroxylase(TH), high-mobility group box 1(HMGB1) and toll-like receptors 4(TLR4) were investigated by immunohistochemistry and Western blot analyses, respectively. After 4 weeks of treatment, forelimb use asymmetry was ameliorated in the 6-OHDA+rTMS group. Consistent with the behavioral tests, rTMS increased TH in the substantia nigra (SN) and the striatum of PD rats. High glial activation and HMGB1/TLR4 expression in the SN and the striatum were observed in the 6-OHDA group, while rTMS alleviated these changes. Conclusions: This study showed that rTMS might be a promising method for alleviating neuroinflammation in PD rat models, and the effects might be mediated through the downregulation of the HMGB1/TLR4 pathway.